Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 4 of 4 publications.

Vincendeau S, Jiang S, Varghese D, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Scailteux LM, Hussain A. Non-metastatic castration-resistant prostate cancer treated with androgen receptor axis targeting agents - French trends. Clin Onco. 2022 Dec 2;6(15):1-9.

Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials. 2022 Sep;120:106860. doi: 10.1016/j.cct.2022.106860

Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AEs) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the Virtual Journal of Managed Care & Specialty Pharmacy 2020 Conference; October 2020. [abstract] J Manag Care Spec Pharm. 2020 Oct; 26(10-a Suppl):S89. Previously presented at the 2020 Virtual ISPOR Asia Pacific Conference.

Jiang S, Varghese D, Appukkuttan S, Corman S, Kebede N, Gnanasakthy K, Macahilig C, Waldeck R, Hussain A. Real-world incidence and management of adverse events (AE) in patients with non-metastatic castrate-resistant prostate cancer receiving apalutamide or enzalutamide. Poster presented at the 2020 Virtual ISPOR Asia Pacific Conference; September 10, 2020. [abstract] Value in Health Regional Issues. 2020 Sep 1; 22(Supplement):S4-5.